|Source:||The seeds of Schisandra chinensis (Turcz.) Baill.|
|Biological Activity or Inhibitors:||1. Schizandrin B enhanced cell survival via reducing apoptosis rate, limited extracellular matrix deposition.
2. Schizandrin B has a potential protective activity against CisPt nephrotoxicity.
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.4971 mL||12.4853 mL||24.9707 mL||49.9413 mL||62.4266 mL|
|5 mM||0.4994 mL||2.4971 mL||4.9941 mL||9.9883 mL||12.4853 mL|
|10 mM||0.2497 mL||1.2485 mL||2.4971 mL||4.9941 mL||6.2427 mL|
|50 mM||0.0499 mL||0.2497 mL||0.4994 mL||0.9988 mL||1.2485 mL|
|100 mM||0.025 mL||0.1249 mL||0.2497 mL||0.4994 mL||0.6243 mL|
J Appl Toxicol. 2014 Dec;34(12):1311-9.
|Protective effects of schizandrin and schizandrin B towards cisplatin nephrotoxicity in vitro.[Pubmed: 24155209]|
|Renal proximal tubular epithelial cells are the main targets of toxic drugs such as cisplatin (CisPt), an alkylating agent indicated for the treatment of solid organ tumors. Current techniques aiming at reducing nephrotoxicity in patients receiving CisPt are still not satisfactory as they can only partially prevent acute kidney injury. New nephroprotective strategies remain to be developed. In the present in vitro study, schizandrin (Schi) and Schizandrin B (Schi B), major phytochemicals from Schisandra chinensis (Turcz.) Baill. fruits, were tested on HK-2 cells along four processes that could help alleviate CisPt toxicity. Results indicated that: (i) both Schi and Schizandrin B enhanced cell survival via reducing apoptosis rate; (ii) only Schi showed moderate effects towards modulation of regeneration capacities of healthy cells; (iii) both Schi and Schizandrin B limited extracellular matrix deposition; and (iv) both compounds could help preventing dedifferentiation processes via the β-catenin pathway. Schi and Schi B present promising activities for future development of protective agents against CisPt nephrotoxicity.|
Nan Fang Yi Ke Da Xue Xue Bao. 2012 Apr;32(4):583-5, 592.
|[Effect of schizandrin B on H(2)O(2)-induced apoptosis of human hepatocytes in vitro: role of Fas pathway].[Pubmed: 22543149]|
|OBJECTIVE: To investigate the role of Fas pathway in H(2)O(2)-induced apoptosis of L02 human hepatocytes and the effect of Schizandrin B on Fas pathway. METHODS: Real-time quantitative PCR was used to detect the expressions of FAS, fas associated death domain protein (FADD) and caspase-8 mRNA in L02 cells exposed to H(2)O(2). Flow cytometry was employed to assess the cell apoptosis. ELISA, Western blotting and spectrophotometric assay were performed to determine the expressions of FAS protein, FADD protein and caspase-8 activity. RESULTS: Within the dose range of 5-15 mol/L, Schizandrin B dose-dependently inhibited FAS and FADD expressions and caspase-8 activation. CONCLUSION: Schizandrin B can partially inhibit H(2)O(2)-induced L02 cell apoptosis possibly by affecting the FAS-FADD-caspase-8 pathway.|
Zhong Yao Cai. 2014 Sep;37(9):1604-8.
|[Determination of lignanoids in seeds of Schisandra chinensis by combinative methods of fingerprint and QAMS].[Pubmed: 25857162]|
|OBJECTIVE: To establish a fingerprint of seeds of Schisandra chinensis (SSC) and develop a method of quantitative analysis of multi-components by single marker (QAMS) for simultaneous determining six lignanoids in SSC. METHODS: Eleven batches of SSC were determined by HPLC and a common mode of fingerprint has been established. A method was developed for QAMS to determine schizandrol A, schizandrol B, schisantherin A, deoxyschizandrin, Schizandrin B and schizandrin C in SSC. Schizandrol A was selected as internal reference; the relative correction factors (RCF)of other five lignanoids to the internal reference were calculated. The contents of the six lignanoids in eleven batches of SSC were determined by both external standard method and QAMS. The QAMS method was evaluated by comparison of its assay results with that of external standard method. RESULTS: There were 24 common peaks in fingerprints of eleven batches of SSC, six of them were identified. The similarities of fingerprints of eleven batches of SSC were over 0.980. The established RCF had a good reproducibility. No significant differences were found between the quantitative results of external standard method and QAMS. CONCLUSION: The developed method is accurate,feasible, and can be used for the qualitative and quantitative analysis of lignanoids in SSC.|
J Ethnopharmacol. 2015 May 26;166:305-12.
|Comparative pharmacokinetics and tissue distribution profiles of lignan components in normal and hepatic fibrosis rats after oral administration of Fuzheng Huayu recipe.[Pubmed: 25794805]|
|ETHNOPHARMACOLOGICAL RELEVANCE: Fuzheng Huayu recipe (FZHY) is formulated on the basis of Chinese medicine theory in treating liver fibrosis. AIM OF THE STUDY: To illuminate the influence of the pathological state of liver fibrosis on the pharmacokinetics and tissue distribution profiles of lignan components from FZHY. MATERIALS AND METHODS: Male Wistar rats were randomly divided into normal group and Hepatic fibrosis group (induced by dimethylnitrosamine). Six lignan components were detected and quantified by ultrahigh performance liquid chromatography-tandem mass spectrometry(UHPLC-MS/MS)in the plasma and tissue of normal and hepatic fibrosis rats. RESULTS: A rapid, sensitive and convenient UHPLC-MS/MS method has been developed for the simultaneous determination of six lignan components in different rat biological samples successfully. After oral administration of FZHY at a dose of 15g/kg, the pharmacokinetic behaviors of schizandrin A (SIA), Schizandrin B (SIB), schizandrin C (SIC), schisandrol A (SOA), Schisandrol B (SOB) and schisantherin A (STA) have been significantly changed in hepatic fibrosis rats compared with the normal rats, and their AUC(0-t) values were increased by 235.09%, 388.44%, 223.30%, 669.30%, 295.08% and 267.63% orderly (P<0.05). Tissue distribution results showed the amount of SIA, SIB, SOA and SOB were significant increased in heart, lung, spleen and kidney of hepatic fibrosis rats compared with normal rats at most of the time point (P<0.05). Meanwhile, the result also reveals that the hepatic fibrosis could delay the peak time of lignans in liver. CONCLUSION: The results proved that the established UHPLC-MS/MS method could be applied to the comparative study on pharmacokinetics and tissue distribution of lignan components in normal and hepatic fibrosis rats. The hepatic fibrosis could alter the pharmacokinetics and tissue distribution properties of lignan components in rats after administration of FZHY. The results might be helpful for guide the clinical application of this medicine.|